BioCentury | Mar 10, 2010
Financial News

BT Pharma raises EUR 13.1 million

...including Edmond de Rothschild Investment Partners. InnoBio is a venture fund managed by CDC Entreprises. BT Pharma...
BioCentury | Oct 13, 2008
Company News

BT Pharma board of directors update

BT Pharma S.A. , Labege, France Business: Cancer Appointed: Thierry Hercend as president of the supervisory board, formerly VP of oncology research at sanofi-aventis Group WIR Staff cancer...
BioCentury | Jan 21, 2008
Company News

BT Pharma, Institut Pasteur deal

...The parties amended a 2002 deal to give BT Pharma rights to combine cyclophosphamide or other undisclosed...
...an immunotherapy delivered using adenylate cyclase vector technology to treat cancer. Under the original deal, BT Pharma...
...The combination therapy is in preclinical testing to treat cancer. Further terms were not disclosed. BT Pharma S.A....
BioCentury | Sep 24, 2007
Company News

BT Pharma management update

BT Pharma S.A. , Labege, France Business: Cancer Hired: Martin Koch as VP of finance and administration, formerly sales director of the oncology division at Cephalon Inc. 's Cephalon Europe unit WIR Staff cancer...
BioCentury | May 29, 2006
Company News

BT Pharma board of directors update

BT Pharma S.A. , Toulouse, France Business: Cancer, Infectious Appointed: Christian Policard, founding partner of Biotech Developpement Conseil WIR Staff...
Items per page:
1 - 5 of 5
BioCentury | Mar 10, 2010
Financial News

BT Pharma raises EUR 13.1 million

...including Edmond de Rothschild Investment Partners. InnoBio is a venture fund managed by CDC Entreprises. BT Pharma...
BioCentury | Oct 13, 2008
Company News

BT Pharma board of directors update

BT Pharma S.A. , Labege, France Business: Cancer Appointed: Thierry Hercend as president of the supervisory board, formerly VP of oncology research at sanofi-aventis Group WIR Staff cancer...
BioCentury | Jan 21, 2008
Company News

BT Pharma, Institut Pasteur deal

...The parties amended a 2002 deal to give BT Pharma rights to combine cyclophosphamide or other undisclosed...
...an immunotherapy delivered using adenylate cyclase vector technology to treat cancer. Under the original deal, BT Pharma...
...The combination therapy is in preclinical testing to treat cancer. Further terms were not disclosed. BT Pharma S.A....
BioCentury | Sep 24, 2007
Company News

BT Pharma management update

BT Pharma S.A. , Labege, France Business: Cancer Hired: Martin Koch as VP of finance and administration, formerly sales director of the oncology division at Cephalon Inc. 's Cephalon Europe unit WIR Staff cancer...
BioCentury | May 29, 2006
Company News

BT Pharma board of directors update

BT Pharma S.A. , Toulouse, France Business: Cancer, Infectious Appointed: Christian Policard, founding partner of Biotech Developpement Conseil WIR Staff...
Items per page:
1 - 5 of 5